Zug, Zug, Switzerland
My mission is to democratize medical innovation for cancer patients by building dynamic, purpose-driven organizations. With a track record of successfully launching breakthrough cancer therapies—from anti-PD1 monoclonal antibodies and PARP inhibitors to first in class Antibody Drug-Conjugates—internationally, I specialize in creating pathways for novel therapeutics. My expertise spans the full spectrum of TA and product strategy. Recent initiatives include indication enabling life-cycle trial design, international early access programs, companion diagnostic launches, registry design and scientific exchange to maximize launch outcomes. As a grounded yet ambitious leader, I balance thoughtful deliberation with decisive action, fostering cross-functional collaboration while embracing calculated risks. Above all, my unwavering commitment to improving patient outcomes drives both my focus and my team's dedication to excellence.
Department Head with 40 HC line reporting Leading Women's Cancer, Hematology, IO Pipeline and Patient Centricity 2 Launches + 1 Line externsion
Senior member of German and EU Management team (Reports: 10 line) 2 Launches across Germany, Austria, Switzerland
Medical Affairs and Strategic Planning Global lead – Patritumab (Anti-Her3 mAb)
Life Cycle Management (indication expansion and marketing support) Early stage R&D portfolio prioritization Clinical development support Start-up experience with ‘build up’ to 10 employees